Tigermed Reports Impressive Annual Results for 2025 Showing Strong Growth in Clinical Research

Tigermed's Outstanding Annual Report for 2025

Hangzhou Tigermed Consulting Co., Ltd., known as Tigermed, has recently shared its annual results for 2025, revealing a promising performance in the global biopharmaceutical and medical device sector. With stock codes 300347.SZ and 3347.HK, the company continues to be a prominent player in providing integrated research and development solutions.

Financial Highlights

During 2025, Tigermed's total revenue reached an impressive RMB 6.83 billion, translating to a gross profit of RMB 1.87 billion. Despite challenges in the global market, the adjusted net profit attributable to its owners stood at RMB 355 million. A significant portion of the revenue was generated from Clinical Trial Solutions, contributing RMB 3.27 billion, while Clinical-related and Lab Services brought in RMB 3.57 billion. Notably, the company reported that 54% of its revenue came from China, amounting to RMB 3.7 billion, while international markets accounted for the remaining 46%.

In terms of growth, Tigermed’s net new bookings soared to RMB 10.16 billion, marking a remarkable 20.6% increase from the previous year. Furthermore, the backlog of contracted revenue extended to RMB 18.2 billion, reflecting a solid upward trajectory in demand for its services.

Employment and Market Influence

As of the end of 2025, Tigermed boasted a workforce of 11,130 employees across 42 countries, including nearly 2,000 employees stationed overseas. The company retained its competitive edge in the Chinese clinical contract research organization (CRO) industry, holding the highest market share. Since its inception, Tigermed has been instrumental in securing 61% of Class I new drug approvals in China, assisting in 49 new drug and 5 medical device approvals within the reporting year.

This year, Tigermed expanded its global footprint by acquiring Micron, a CRO based in Japan, and Shanghai Bioquick, both contributing to enhanced service capabilities. The company further grew its teams in Malaysia and India to bolster its global research and development support.

Technological Advancements

In alignment with its commitment to innovation, Tigermed developed the YIYa AI LLM platform, which facilitates AI-powered translation and content generation. These advancements are part of Tigermed's ongoing efforts to optimize operational efficiency and enhance client service.

Tigermed's clinical trial solutions demonstrated significant growth, with 663 ongoing drug clinical trials and 744 medical device and IVD projects as of December 31, 2025. The company successfully added 50 new U.S. FDA Investigational New Drug (IND) projects and supported 85 applications for clinical approval across multiple countries.

Commitment to Quality and Expansion

Achieving a 'zero-defect' status during FDA inspections exemplifies Tigermed's adherence to high-quality standards. Additionally, its strategic maneuvers in securing new business ventures, including 255 new pharmacovigilance projects, signal a proactive approach toward expanding its service range.

With ongoing projects and a significant number of clinical trials in progress, Tigermed is not only focused on local market dominance but also enhancing its international presence. Its U.S. workforce exceeded 1,000, and new offices in Malaysia signify a robust expansion strategy aimed at penetrating new markets and fostering innovation.

Management Insights

The leadership at Tigermed is confident about the company’s trajectory in the coming years. Dr. Xiaoping Ye, Co-founder and Chairman, emphasized the importance of embedding its development into broader industry ecosystems to support innovative drug research and development. President Ms. Xiaochun Cao echoed these sentiments, highlighting the shift toward creating an interconnected global innovation network.

Looking forward, Tigermed remains dedicated to pioneering advancements in clinical research and ensuring timely delivery of innovative therapies to patients worldwide. With strategic partnerships and cutting-edge technology, Tigermed is set to navigate the rapidly evolving biopharmaceutical landscape effectively.

Conclusion

Tigermed's impressive performance for the fiscal year 2025 reflects not only growth in revenue and market share but also a commitment to technological integration and quality service. As it continues to expand its reach and capabilities, the company is well-positioned to influence the future of global healthcare significantly.